|Day Low/High||45.95 / 45.99|
|52 Wk Low/High||22.11 / 46.01|
We took advantage of some buying opportunities this week and added shares to three of our model portfolio positions.
NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) is scheduled to present at the 15 th Annual Bio CEO & Investor Conference in New York on Monday, February 11, 2013 at 10:30 a.
During a week filled with earnings action and economic reports, we booked some gains in one model portfolio name.
The Journal of Parenteral and Enteral Nutrition recently published clinical considerations and best-practice recommendations for introducing Gattex ® (teduglutide [rDNA origin]) for injection into the management...
With major U.S. indices near all-time highs, we will continue to scour the universe of low-dollar stocks for buying opportunities.
Amid an options expiration week that saw volatility in U.S. stocks drop, we added a new name to the model portfolio.
Biotech columnist Adam Feuerstein answers readers' questions about health-care companies
The best and worst biotech and drug companies to emerge from last week's investor conference.
Earnings season kicked off this week amid low market volatility, and we closed out one model portfolio position.
NPS Pharmceuticals and Exact Sciences are two good plays in health while Bank of America should outshine other banks, Cramer said.
On down days investors need safe places, said Cramer, who kicked off a weeklong series of investing trends for 2013.
Stocks kicked off 2013 with a bang, and several model portfolio delivered double-digit percentage gains this week.
A preview of what to expect from biotech stocks at the next week's 'Life Sciences Lollapalooza.'
A debate about NPS Pharma, Gattex and the sustainability of orphan drug pricing with Forbes' Matt Herper
This pharmaceutical name is about to launch an important product and our largest holding continues to increase in value.
NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) will present at the 31 st Annual J.
NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) will host a conference call to discuss its commercialization plan for Gattex, including the cost of therapy, today at 5:00 p.
TheStreet's Adam Feuerstein gazes into his crystal ball to offer his 2013 biotech stock forecast.
It was a quiet week for the model portfolio, but we would consider adding to our positions on the next market pullback.
NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today announced that it has established a ...
Amid a volatile week of trading, we trimmed one model portfolio name and added shares to two others.
NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today announced that the U.
In the midst of today's broad market weakness, we will put cash to work by adding shares to this biotech name.
As we begin to position the model portfolio for 2013, we added shares to one position this week.
Senior columnist Adam Feuerstein says three big FDA drug approval decisions are the next big things to watch in biotech.
It was a volatile week for the market but a quiet one for the model portfolio, as we continued to search for new names.
It was a quiet week for the model portfolio, but we will continue to monitor the market's volatility for opportunities.
NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a biopharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, announced today that its Phase 3 study of Gattex ...
NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) will present at the 2012 Deutsche Bank BioFEST Conference in Boston on Tuesday, December 4, 2012 at 10:10 a.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.